Logo
x

Search

Subscribe Now

RUXCOVID Study

Novartis' Ruxolitinib Fails to Meet its Primary Endpoint in P-lll RUXCOVID Study for COVID-19

Novartis' Ruxolitinib Fails to Meet its Primary Endpoint in P-lll RUXCOVID Study for COVID-19

  • December 14, 2020
Incyte Initiates P-III RUXCOVID Study Evaluating Jakafi (ruxolitinib) to Treat Patients with COVID-19 Associated Cytokine Storm

Incyte Initiates P-III RUXCOVID Study Evaluating Jakafi (ruxolitinib) to Treat Patients with COVID-19 Associated Cytokine Storm

  • April 20, 2020
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.